Dietary Compound Resveratrol Is a Pan-BET Bromodom... - BV FAPESP
Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor

Full text
Author(s):
Dutra, Luiz Antonio [1, 2, 3] ; Heidenreich, David [2, 3] ; Bernardes da Silva, Gabriel Dalio [1] ; Chin, Chung Man [1] ; Knapp, Stefan [2, 3] ; dos Santos, Jean Leandro [1]
Total Authors: 6
Affiliation:
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara - Brazil
[2] Goethe Univ, Inst Pharmaceut Chem, D-60438 Frankfurt - Germany
[3] Goethe Univ, Buchmann Inst Life Sci, D-60438 Frankfurt - Germany
Total Affiliations: 3
Document type: Journal article
Source: NUTRIENTS; v. 9, n. 11 NOV 2017.
Web of Science Citations: 6
Abstract

The chemopreventive and anticancer effects of resveratrol (RSV) are widely reported in the literature. Specifically, mechanisms involving epigenetic regulation are promising targets to regulate tumor development. Bromodomains act as epigenetic readers by recognizing lysine acetylation on histone tails and boosting gene expression in order to regulate tissue-specific transcription. In this work, we showed that RSV is a pan-BET inhibitor. Using Differential Scanning Fluorimetry (DSF), we showed that RSV at 100 mu M increased the melting temperature (Delta Tm) of BET bromodomains by around 2.0 degrees C. The micromolar dissociation constant (K-d) range was characterized using Isothermal Titration Calorimetry (ITC). The RSV K-d value accounted to 6.6 mu M in case of BRD4(1). Molecular docking proposed the binding mode of RSV against BRD4(1) mimicking the acetyl-lysine interactions. All these results suggest that RSV can also recognize epigenetic readers domains by interacting with BET bromodomains. (AU)

FAPESP's process: 15/19531-1 - Targeting histone deacetylase (HDAC-1 and HDAC-2) as mechanisms to induce fetal hemoglobin in sickle cell disease
Grantee:Jean Leandro dos Santos
Support Opportunities: Regular Research Grants
FAPESP's process: 16/08880-8 - Synthesis and pharmacological evaluation of Bromodomain inhibitors (BRD-3) designed as fetal hemoglobin inducers
Grantee:Gabriel Dalio Bernardes da Silva
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 14/03945-9 - Design, synthesis and pharmacological evaluation of new resveratrol derivatives useful for dyslipidemia treatment
Grantee:Luiz Antonio Dutra
Support Opportunities: Scholarships in Brazil - Doctorate